MX343607B - Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. - Google Patents

Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.

Info

Publication number
MX343607B
MX343607B MX2013005067A MX2013005067A MX343607B MX 343607 B MX343607 B MX 343607B MX 2013005067 A MX2013005067 A MX 2013005067A MX 2013005067 A MX2013005067 A MX 2013005067A MX 343607 B MX343607 B MX 343607B
Authority
MX
Mexico
Prior art keywords
receptor alpha
folate receptor
fra
subject
methods
Prior art date
Application number
MX2013005067A
Other languages
English (en)
Other versions
MX2013005067A (es
Inventor
Grasso Luigi
J O'shannessy Daniel
Wan Shanhong
Chao Qimin
Brooke Somers Elizabeth
Original Assignee
Morphotek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphotek Inc filed Critical Morphotek Inc
Publication of MX2013005067A publication Critical patent/MX2013005067A/es
Publication of MX343607B publication Critical patent/MX343607B/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57423—Specifically defined cancers of lung
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/82—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving vitamins or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a métodos y equipos para evaluar si un sujeto padece de un cáncer que expresa FRa, métodos y equipos para anticipar el progreso de un cáncer de ovario en un sujeto que padece de un cáncer que expresa FRa, métodos y equipos para evaluar el nivel de riesgo que tiene un sujeto de desarrollar un cáncer que expresa FRa, y métodos para estratificar a un sujeto con un cáncer que expresa FRa en grupos de terapia de cáncer. Los métodos implican determinar el nivel de receptor alfa de folato FRa que no está enlazado a una célula en una muestra derivada del sujeto, y comparar este nivel con el nivel de FRa en una muestra de control.
MX2013005067A 2010-11-05 2011-11-04 Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato. MX343607B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41049710P 2010-11-05 2010-11-05
US201161508444P 2011-07-15 2011-07-15
PCT/US2011/059411 WO2012061759A2 (en) 2010-11-05 2011-11-04 Folate receptor alpha as a diagnostic and prognostic marker for folate receptor alpha-expressing cancers

Publications (2)

Publication Number Publication Date
MX2013005067A MX2013005067A (es) 2013-07-02
MX343607B true MX343607B (es) 2016-11-11

Family

ID=45003076

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016011546A MX368394B (es) 2010-11-05 2011-11-04 Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.
MX2013005067A MX343607B (es) 2010-11-05 2011-11-04 Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016011546A MX368394B (es) 2010-11-05 2011-11-04 Receptor alfa de folato como marcador de diagnostico y pronostico para canceres que expresan receptor alfa de folato.

Country Status (14)

Country Link
US (1) US20120207771A1 (es)
EP (2) EP3130605B1 (es)
JP (2) JP6224456B2 (es)
KR (2) KR102057438B1 (es)
CN (2) CN108562744A (es)
AU (3) AU2011323124C1 (es)
BR (1) BR112013011072B1 (es)
CA (1) CA2816991C (es)
ES (2) ES2780192T3 (es)
IL (2) IL225871B (es)
MX (2) MX368394B (es)
RU (2) RU2764592C2 (es)
SG (3) SG10201509145XA (es)
WO (1) WO2012061759A2 (es)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060239910A1 (en) * 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
AR080301A1 (es) 2010-02-24 2012-03-28 Immunogen Inc Anticuerpos e inmunoconjugados del receptor 1 de folato y sus usos
US20120189620A1 (en) * 2011-01-21 2012-07-26 Emory University Methods for treating non-functioning pituitary adenoma
WO2012119077A1 (en) * 2011-03-02 2012-09-07 Morphotek Inc. Co -administration of eribulin and farletuzumab for the treatment of breast cancer
RS56916B1 (sr) 2011-04-01 2018-05-31 Immunogen Inc Postupci za povećanje efikasnosti terapije kancera usmerene na folr1
AU2012284321C1 (en) 2011-07-15 2017-07-13 Eisai R&D Management Co., Ltd. Anti-folate receptor alpha antibodies and uses thereof
ES2766836T3 (es) * 2012-05-15 2020-06-15 Eisai Inc Métodos para el tratamiento de cáncer gástrico
EP2890717B1 (en) * 2012-08-31 2020-03-04 ImmunoGen, Inc. Diagnostic assays and kits for detection of folate receptor 1
MX2015017950A (es) 2013-06-20 2016-05-10 Morphotek Inc Metodos para el tratamiento de cancer de ovario.
UA120166C2 (uk) 2013-08-30 2019-10-25 Іммуноджен, Інк. Антитіло, що специфічно зв'язується з folr1, та спосіб виявлення рецептора фолієвої кислоти 1
DK3653228T3 (da) * 2013-10-08 2024-07-15 Immunogen Inc Anti-folr1-immunkonjugatdoseringsregimer
WO2016079050A1 (en) 2014-11-20 2016-05-26 F. Hoffmann-La Roche Ag Combination therapy of t cell activating bispecific antigen binding molecules cd3 abd folate receptor 1 (folr1) and pd-1 axis binding antagonists
CA2983126A1 (en) 2015-04-17 2016-10-20 Morphotek, Inc. Methods for treating lung cancer
MA42844A (fr) 2015-09-17 2018-07-25 Immunogen Inc Combinaisons thérapeutiques comprenant des immunoconjugués anti-folr1
CA3033077C (en) 2016-08-12 2024-06-18 L.E.A.F. Holdings Group Llc Alpha and gamma-d polyglutamated antifolates and uses thereof
JP7072571B2 (ja) * 2016-11-23 2022-05-20 エーザイ・アール・アンド・ディー・マネジメント株式会社 抗葉酸受容体アルファ抗体およびその使用
CN107353325B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽1及其应用
CN107446021B (zh) * 2017-07-26 2020-08-11 中国药科大学 叶酸受体α特异性结合肽5及其应用
CN107446020B (zh) * 2017-07-28 2019-10-01 中国药科大学 叶酸受体α特异性结合肽2及其应用
JP2020532751A (ja) * 2017-09-05 2020-11-12 イミュノジェン， インコーポレイテッド 患者の試料中のヒト葉酸受容体１を検出するための方法
US12076402B2 (en) 2018-02-07 2024-09-03 L.E.A.F. Holdings Group Llc Alpha polyglutamated antifolates and uses thereof
WO2019157129A1 (en) 2018-02-07 2019-08-15 L.E.A.F. Holdings Group Llc Alpha polyglutamated pralatrexate and uses thereof
CN111954531A (zh) 2018-02-07 2020-11-17 L.E.A.F.控股集团公司 α聚谷氨酸化培美曲塞及其用途
US12048767B2 (en) 2018-02-14 2024-07-30 L.E.A.F. Holdings Group Llc Gamma polyglutamated pralatrexate and uses thereof
WO2019160734A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated lometrexol and uses thereof
CA3090992A1 (en) 2018-02-14 2019-08-22 L.E.A.F. Holdings Group Llc Gamma polyglutamated tetrahydrofolates and uses thereof
US11873335B2 (en) * 2018-03-13 2024-01-16 Phanes Therapeutics, Inc. Anti-folate receptor 1 antibodies and uses thereof
EP3935581A4 (en) 2019-03-04 2022-11-30 Iocurrents, Inc. DATA COMPRESSION AND COMMUNICATION USING MACHINE LEARNING
AU2020265568A1 (en) 2019-04-29 2021-11-04 Immunogen, Inc. Biparatopic FR-alpha antibodies and immunoconjugates
WO2022256507A1 (en) * 2021-06-04 2022-12-08 Immunogen, Inc. Treatment of cancer in patients with soluble fr-alpha
CN117700557B (zh) * 2024-02-05 2024-04-30 卡秋(江苏)生物科技有限公司 一种特异性结合叶酸受体α的抗体或抗原结合片段

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5646253A (en) 1994-03-08 1997-07-08 Memorial Sloan-Kettering Cancer Center Recombinant human anti-LK26 antibodies
DK1589107T3 (da) 1992-08-21 2010-04-26 Univ Bruxelles Immonuglobuliner uden lette kæder
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
ATE267877T1 (de) 1993-01-07 2004-06-15 Sequenom Inc Dns - sequenzierung durch massenspektronomie
JPH08507926A (ja) 1993-03-19 1996-08-27 シーケノム・インコーポレーテツド エキソヌクレアーゼ分解を介した質量分析法によるｄｎａ配列決定
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
EP0971946B1 (en) 1997-01-21 2006-07-05 The General Hospital Corporation Selection of proteins using rna-protein fusions
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6933108B2 (en) * 1999-12-09 2005-08-23 The Regents Of The University Of California Methods and compositions for use in the treatment of filovirus mediated disease conditions
US7741019B2 (en) * 2000-11-01 2010-06-22 Mount Sinai Hospital Detection of ovarian cancer
US20100120078A1 (en) * 2001-08-16 2010-05-13 Tony Baker Urine Stabilization System
AU2002340683C1 (en) * 2001-11-13 2009-11-12 Id Biomedical Corporation Of Quebec Polypeptides of pseudomonas aeruginosa
AU2003253589A1 (en) * 2002-03-26 2003-11-10 Centocor, Inc. Epitope mapping using nuclear magnetic resonance
WO2004082463A2 (en) * 2003-03-17 2004-09-30 Medical College Of Ohio Folate receptor gene modulation for cancer diagnosis and therapy
WO2004113388A2 (en) * 2003-05-23 2004-12-29 Morphotek, Inc. Anti alpha - folate - receptor - tetramer antibodies
JP2007512807A (ja) * 2003-10-28 2007-05-24 バイエル ヘルスケア アーゲー 悪性腫瘍の処置に対する応答予測のための方法および組成物
AU2005214331B2 (en) 2004-02-12 2011-09-15 Eisai, Inc. Monoclonal antibodies that specifically bind to folate receptor alpha
WO2006105141A1 (en) * 2005-03-30 2006-10-05 Purdue Research Foundation Method for cancer prognosis using cellular folate vitamin receptor quantification
US20060239910A1 (en) * 2005-04-22 2006-10-26 Morphotek Inc. Antibodies with immune effector activity and that internalize in folate receptor alpha-positive cells
KR20080114689A (ko) * 2006-02-09 2008-12-31 유니버시티 오브 사우스 플로리다 증가된 ｂｃｌ-2에 의한 암의 발견
CA2685300C (en) * 2006-06-01 2017-01-03 Mayo Foundation For Medical Education And Research Immunity to folate receptors
EP1900752A1 (en) * 2006-09-15 2008-03-19 DOMPE' pha.r.ma s.p.a. Human anti-folate receptor alpha antibodies and antibody fragments for the radioimmunotherapy of ovarian carcinoma
US7754698B2 (en) 2007-01-09 2010-07-13 Isis Pharmaceuticals, Inc. Modulation of FR-alpha expression
AU2008317404B2 (en) * 2007-10-19 2014-12-18 Cell Signaling Technology, Inc. Cancer classification and methods of use
WO2009132081A2 (en) 2008-04-24 2009-10-29 The Research Foundation Of State University Of New York Monoclonal antibody-based targeting of folate receptors
US20110177525A1 (en) * 2010-01-19 2011-07-21 Predictive Biosciences, Inc. Antibodies and methods of diagnosing diseases
EP2606353A4 (en) * 2010-08-18 2014-10-15 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASE

Also Published As

Publication number Publication date
WO2012061759A2 (en) 2012-05-10
JP2013544354A (ja) 2013-12-12
RU2630608C2 (ru) 2017-09-11
EP3130605A1 (en) 2017-02-15
CA2816991C (en) 2020-06-09
US20120207771A1 (en) 2012-08-16
RU2017129266A3 (es) 2021-01-25
JP6224456B2 (ja) 2017-11-01
KR101931936B1 (ko) 2018-12-26
AU2018201760A1 (en) 2018-04-05
AU2011323124C1 (en) 2016-09-22
JP2018036270A (ja) 2018-03-08
ES2627061T3 (es) 2017-07-26
JP6554152B2 (ja) 2019-07-31
CN108562744A (zh) 2018-09-21
AU2018201760B2 (en) 2019-07-25
IL225871B (en) 2018-08-30
AU2011323124B2 (en) 2016-02-25
SG10201701933XA (en) 2017-05-30
BR112013011072B1 (pt) 2021-02-02
SG189957A1 (en) 2013-06-28
BR112013011072A2 (pt) 2017-06-20
IL225871A0 (en) 2013-06-27
CN103687618A (zh) 2014-03-26
EP2635304A2 (en) 2013-09-11
KR20140024838A (ko) 2014-03-03
EP2635304B1 (en) 2017-03-08
SG10201509145XA (en) 2015-12-30
ES2780192T3 (es) 2020-08-24
EP3130605B1 (en) 2020-01-08
RU2764592C2 (ru) 2022-01-18
RU2013125772A (ru) 2014-12-10
MX368394B (es) 2019-10-01
KR102057438B1 (ko) 2019-12-20
AU2016203408A1 (en) 2016-06-16
MX2013005067A (es) 2013-07-02
WO2012061759A3 (en) 2012-07-26
CA2816991A1 (en) 2012-05-10
IL260590B (en) 2020-01-30
KR20180137587A (ko) 2018-12-27
AU2011323124A1 (en) 2013-05-09
RU2017129266A (ru) 2019-02-04

Similar Documents

Publication Publication Date Title
MX343607B (es) Receptor alfa de folato como marcador de diagnóstico y pronóstico para cánceres que expresan receptor alfa de folato.
IN2013CN01129A (es)
GB2503148A (en) Biomarker panels diagnostic methods and test kits for ovarian cancer
GB2531881A (en) Method of isolating circulating tumor cells
NZ629074A (en) Biomarkers for gastric cancer and uses thereof
EA201390762A1 (ru) Новые биомаркеры для предсказания исхода противораковой иммунотерапии
CY1120600T1 (el) Αντισωματα κατα του υποδοχεα φυλλικου αλφα και χρησεις αυτων
EP4219765A3 (en) Prostate cancer prognosis using biomarkers
MX2015006680A (es) Composiciones y metodos para diagnosticar tumores de tiroides.
NZ606687A (en) Ratio based biomarkers and methods of use thereof
MX357550B (es) Microarn plasmaticos para la deteccion de cancer colorrectal temprano.
MX340453B (es) Biomarcadores para cancer de pulmon.
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
WO2009120561A3 (en) Methods and gene expression signature for assessing growth factor signaling pathway regulation status
MX369628B (es) Genes nano46 y metodos para predecir el resultado del cancer de mama.
EA201370063A1 (ru) Фосфолипидом рака
NZ621733A (en) Lung cancer biomarkers and uses thereof
EA201691499A1 (ru) Диагностика с помощью циркулирующих опухолевых клеток биомаркеров, позволяющих предсказывать резистентность по отношению к направленным на андрогеновый рецептор (ar) терапиям
WO2012074904A3 (en) Methods and systems for evaluating the sensitivity or resistance of tumor specimens to chemotherapeutic agents
MX2016006125A (es) Procedimiento, matriz y uso de los mismos.
NZ621638A (en) Dna methylation in colorectal and breast cancer diagnostic methods
WO2011113047A3 (en) Compositions and methods for characterizing breast cancer
WO2014205184A3 (en) Classification system, methods and kit for classifying. predicting and treating breast cancer
BR112017016808A2 (pt) biomarcadores para câncer pancreático
BR112012031444A2 (pt) método, arranjo e uso do mesmo

Legal Events

Date Code Title Description
FG Grant or registration